ATAI Life Sciences

This clinical-stage biopharmaceutical company, based in Germany, was established in 2018. It is dedicated to the development of treatments for a variety of mental health disorders. The company operates through several subsidiaries including DemeRx IB, Inc., InnarisBio, Inc., and others. Florian Brand currently holds the position of CEO.